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CORRESPONDENCE
Letters to the Editor
Anemia in Patients
With Advanced Heart Failure
We applaud Nanas et al. (1) on their attempt to elucidate the
etiology of anemia in patients with advanced heart failure. We
believe that clarification of some issues in their study regarding the
definitions of anemia as well as potential introduction of surveil-
lance bias would further improve its relevance.
Defining anemia as “clinically significant” deviates from other
standardized definitions—the World Health Organization (2) or
Centers for Disease Control and Prevention criteria (3)—with
implications for anemia prevalence. In addition, surveillance bias
seems likely as only 2 of 37 patients were female derived from an
unknown denominator.
The ferritin concentration used by the investigators (17
ng/ml, 38 pmol/l) is lower than other surveys (4) and expert
reviews (5), hence, had a different threshold been applied, addi-
tional patients with iron deficiency anemia may have been discov-
ered. Finally, the meaning of “the absence of iron stores” in the
bone marrow is unclear without quantification or reporting of
the stain used or inter-reader reliability. Additional data on the
saturation index and correlation of serum markers with histo-
logical bone marrow findings would be most useful to other
researchers in this area and potentially enhance the clinical
applicability of the data.
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Is Anemia in
Chronic Heart Failure
Caused by Iron Deficiency?
With great interest we read the recent study in JACC by Nanas
et al. (1), which provides important insight into the etiology of
anemia in patients with advanced heart failure. Anemia is
prevalent in chronic heart failure (CHF) patients and is
associated with an impaired prognosis (2). The etiology of
anemia is likely to be multifactorial (3) although prospective
studies on the etiology of anemia in CHF are sparse. The main
finding of the study by Nanas et al. (1) was that, although serum
iron and ferritin levels were normal, iron stores in the bone
marrow were significantly depleted. The investigators therefore
concluded that anemia in these patients is predominantly
caused by iron deficiency, which is masked by inflammation-
associated up-regulation of ferritin, thereby disqualifying fer-
ritin as a diagnostic modality in CHF. Regretfully, Nanas et al.
(1) do not provide mechanistic insight into the cause of iron
deficiency, as it is questionable whether the depleted iron stores
in the bone marrow truly indicate systemically depleted iron
stores.
One of the hallmarks of anemia of chronic disease is the
marked dysregulation of iron homeostasis (4). Proinflammatory
cytokines such as interleukin (IL)-6, IL-1, and tumor necrosis
factor-alpha divert iron from the circulation to the reticuloen-
dothelial system in the lymph nodes and the spleen. This is
facilitated through increased erythrophagocytosis, increased
production of ferritin, increased uptake of ferrous iron, and
reduced release of iron by macrophages, resulting in a “reticu-
loendothelial block” (5). Accumulation of iron in storage sites
of the reticuloendothelial system results in reduced serum iron
levels and depleted iron stores in the bone marrow, thereby
limiting the availability of iron for erythropoiesis. Thus, al-
though anemia of chronic disease is associated with iron-
restricted erythropoiesis, systemic iron stores may be adequate
or even slightly elevated. As CHF is associated with up-
regulation of these cytokines, the depleted iron stores in the
bone marrow aspirates of the patients presented by Nanas et al.
(1) might therefore result from a “reticuloendothelial block”
rather than true iron deficiency. Thus, the implementation of
bone marrow aspiration to evaluate iron stores in anemic CHF
patients, as suggested by the researchers, will fail to differentiate
between nutritional iron deficiency and anemia of chronic
disease.
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Reply
We thank Dr. Ezekowitz and Dr. Westenbrink et al. for their
interest in our recent study (1). In general, their letters raise issues
and questions that only further research can answer. Our study
design did not allow the drawing of conclusions regarding the
prevalence of anemia, and the only apparent explanation for the
under-representation of women (2 of 37 patients) is that far fewer
women than men are admitted to our hospital. Our study focused
on patients with “clinically significant” anemia (hemoglobin con-
tent 12 g/dl in men and 11.5 g/dl in women) who not only
needed to be treated, but also had to undergo extensive diagnostic
tests, including bone marrow aspiration.
A ferritin concentration 30 ng/ml, used instead of 17 ng/ml
as an indication of depleted iron stores, is associated with a higher
positive predictive value for iron-deficiency anemia (2). However,
using this higher ferritin concentration increased the number
(proportion) of patients from 2 (7.4%) to only 5 of 27 (18.5%)
patients. Thus, ferritin remains an unreliable marker of iron
deficiency in patients suffering from heart failure. Unfortunately,
we did not measure their saturation index.
We agree that our study does not provide insights into the
mechanism(s) of iron deficiency. However, in our discussion we do
emphasize that “iron deficiency anemia in these desperately ill
patients. . . seems to be multifactorial and at least partially the
result of a defective release of iron from cells,” although we do not
have the data to support this hypothesis.
Although it is, indeed, likely that some iron accumulates in
storage sites of the reticulo-endothelial system in these patients,
this accumulation would not be limited to the liver and spleen, and
would include macrophages in the bone marrow. Smears of the
latter are stained for iron with standard Prussian blue and are
counterstained with safranin. With this stain, the hemosiderin
granules appear as blue/green and the cells are purple/red. In
iron-deficiency anemia, by definition, hemosiderin granules are not
detected by photomicroscopy either in the macrophages of the
bone marrow or in the erythroblasts (3). Such was the case in 25
patients whose iron stores were depleted (grade 0) out of 27
patients included in our study. In addition, patients presenting
with chronic heart failure respond to intravenous iron replacement
(4) supporting the hypothesis of a central role played by iron
deficiency in this clinical setting.
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